CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
Oleoylethanolamide (OEA) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05252949
NCT05252949N/ACompleted
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Oleoylethanolamide (OEA) for Targeting Lipid Metabolism in Gulf War Illness

Roskamp Institute Inc.·interventional·Posted Feb 23, 2022·Updated Aug 8, 2025

In Brief

A clinical study evaluating Oleoylethanolamide (OEA) and Placebo for Gulf War Illness. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The study is a single site, randomized, double-blind, placebo-controlled study with an open label extension to evaluate the effects of Oleoylethanolamine (OEA) on blood lipid and immune biomarkers in participants with Gulf War Illness (GWI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGulf War Illness
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 23, 2022
Enrollment StartJun 10, 2021
Primary CompletionSep 30, 2024
Study CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 4.4 years ago

Interventions

Oleoylethanolamide (OEA)dietary

Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.

Placebodietary

Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.